- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Non-small cell lung cancer (NSCLC)
- Meeting Date: December 2024
- Public Summary Document (PSD) December 2024 PBAC Meeting - (PDF 983KB)
- Public Summary Document (PSD) December 2024 PBAC Meeting - (Word 647KB)
Nivolumab – December 2024
Nivolumab: Injection concentrate for I.V. infusion 40 mg in 4 mL, Injection concentrate for I.V. infusion 100 mg in 10 mL; Opdivo®
Last updated
30 May 2025